



#7
2/8/01

February 5, 2001

Micheline Gravelle B.Sc., M.Sc. (Immunol.)
416 957 1682 mgravelle@bereskinparr.com

Your Reference: 09/442,143
Our Reference: 9579-14

The Commissioner of Patents
& Trademarks
Washington, D.C. 20231
U.S.A.

RECEIVED

FEB 6 2001

TEC 1 1600/2900

Dear Sir:

Re: RESPONSE TO OFFICE ACTION FOR RESTRICTION PURPOSES ONLY
United States Patent Application No. 09/442,143
Entitled: Methods of Modulating Immune Coagulation
Inventors: Gary Levy and David A. Clark
Filing Date: November 15, 1999
Examiner: Karen Clemens
Art Unit: 1644

This is responsive to the Office Action, for restriction purposes only, mailed January 9, 2001 for which a response is due by February 9, 2001.

The Examiner has required restriction to one of sixteen inventions under 35 U.S.C. 121 as set out in the Office Action.

Applicants elect to prosecute the Group III invention, the claims readable thereon being claims 2, 3-5 and 17 (drawn to a method of preventing or treating fetal loss by administration of an Fgl2 specific antibody). This is without prejudice to Applicants filing divisional applications to the Groups I, II and IV-XVI inventions.

If additional fees are required, please charge the fees to our Deposit Account No. 02-2095.